Merck, Inc.
🇵🇭Philippines
A Study to Investigate a Research Drug as an Aid for Smoking Cessation in Chronic Cigarette Smokers (0364-007)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT00109135
An Investigational Drug Study in Obese (Considerably Overweight) Patients (0364-006)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 500
- Registration Number
- NCT00109148
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
Phase 1
Terminated
- Conditions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00109109
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 180
- Registration Number
- NCT00109122
Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-13
- Last Posted Date
- 2015-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 330
- Registration Number
- NCT00108017
Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-03-30
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 441
- Registration Number
- NCT00106704
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-29
- Last Posted Date
- 2009-04-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 52
- Registration Number
- NCT00106626
A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-03-22
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 103
- Registration Number
- NCT00106145
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
- First Posted Date
- 2005-03-16
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 685
- Registration Number
- NCT00105534
- Locations
- 🇺🇸
Taustine Eye Center, Louisville, Kentucky, United States
🇺🇸Charlotte Eye, Ear, Nose, and Throat, Charlotte, North Carolina, United States
🇺🇸Precision Eye Care, Huntington, New York, United States
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
- First Posted Date
- 2005-03-15
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 743
- Registration Number
- NCT00105469
- Locations
- 🇺🇸
Alan Shuster, MD, Jupiter, Florida, United States
🇺🇸Children's Eye Physicians, Littleton, Colorado, United States
🇺🇸Pasco Eye Institute, New Port Richey, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath